The FDA declined on November 20 to approve Capricor Therapeutics’ deramiocel for Duchenne muscular dystrophy, saying serious problems with its HOPE-3 trial made the data unreliable as evidence of effectiveness. Capricor disputes that assessment and says its results support approval. Source Source
Bloomberg described the decision as the therapy’s second FDA rejection. Capricor shares fell 77% in extended trading, Reuters reported. Source Source
Capricor was seeking approval for the experimental cell therapy to preserve arm and hand function. Duchenne is a fatal genetic disease that primarily affects boys, progressively weakening muscles and causing loss of mobility and heart complications. Source
The dispute goes to the trial’s foundations
The FDA says an inspection identified unauthorized retrospective changes to HOPE-3’s statistical analysis plan, violations of study-blinding procedures and other protocol violations. Blinding is intended to keep patients and researchers from knowing who received treatment. Source Source
The FDA says those problems cannot be fixed retrospectively, leaving HOPE-3’s data unreliable as a basis for approval. Its objection goes beyond the size or clinical importance of any reported benefit. Source
The FDA says HOPE-3 failed to meet its pre-specified primary and secondary efficacy endpoints, the study’s planned measures of effectiveness. CEO Linda Marbán, by contrast, said in Capricor’s release that HOPE-2 and HOPE-3 both met their primary endpoints. Source Source
“We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval,” Marbán said in the release. She separately called the rejection “indefensible” in comments reported by Reuters. Source Source
A narrower application still fell short
After a July 29 advisory committee meeting, Capricor shifted its proposed use from treating Duchenne-related cardiomyopathy, or heart-muscle disease, to treating upper-limb impairment. It also submitted additional evidence, including 24-month findings from HOPE-3’s open-label extension. The FDA says it reviewed that evidence and still found the application insufficient. Source
Deramiocel remains investigational and has not been approved for commercial use in any indication. Source
What comes next
The FDA also issued a separate Regulatory Responsibility Letter and said Capricor would have an opportunity to address the issues raised there. That opportunity is distinct from the agency’s conclusion that HOPE-3’s data-integrity deficiencies cannot be repaired retrospectively. Source
Capricor reported approximately $198.5 million in cash, cash equivalents, restricted cash and marketable securities as of September 30. The company believes those resources can fund planned operations for at least the next 12 months and says it is reviewing operating costs to extend that runway. Source
Capricor’s November 20 release said it was reviewing the FDA letter and would share next steps after completing that evaluation; it gave no resubmission timetable. The company scheduled a conference call and webcast for Monday, November 23, at 8:30 a.m. ET. Source
Comments